The third quarter of this year brought numerous high-dollar False Claims Act (FCA) settlements involving a variety of industries and alleged conduct.Continue Reading False Claims Act Settlements to Know from Q3 2024
Innovasis Settlement Implications
We recently co-authored an article published by Law360 detailing what the $12 million settlement of the U.S. Department of Justice’s (DOJ) case against medical device maker Innovasis Inc. may mean for other Anti-Kickback Statute (AKS) cases. Continue Reading Innovasis Settlement Implications
False Claims Act Settlements to Know from Q2 2024
Halfway through 2024, the government’s False Claims Act (FCA) enforcement efforts show few signs of letting up. Last month alone, the Department of Justice (DOJ) announced at least five eight-figure FCA settlements, resolving allegations ranging from unlawful kickbacks to upcoding to improper subcontracting to cybersecurity violations. Continue Reading False Claims Act Settlements to Know from Q2 2024
The Tale of an AKS Self-Disclosure
Last week, the Department of Justice (DOJ) announced a $12 million settlement with spinal device manufacturer, Innovasis Inc. (Innovasis) and senior executives Brent Felix and Garth Felix related to allegations that they violated the False Claims Act (FCA) by paying kickbacks to surgeons to induce their use of its spinal devices. Continue Reading The Tale of an AKS Self-Disclosure
Seventh Circuit Upholds FCA Judgment Against Constitutional Challenge, Avoids Causation Circuit Split
On May 2, the U.S. Court of Appeals for the Seventh Circuit affirmed a False Claims Act (FCA) trial verdict in part, holding that the judgment was not constitutionally excessive under the Eighth Amendment. Continue Reading Seventh Circuit Upholds FCA Judgment Against Constitutional Challenge, Avoids Causation Circuit Split
False Claims Act Settlements to Know from Q1 2024
Despite the recent downward trend in DOJ healthcare industry settlements, the first quarter of 2024 saw many noteworthy False Claims Act (FCA) and civil healthcare fraud settlements related to alleged kickbacks, medically unnecessary services and equipment, pharmaceutical issues and Controlled Substances Act violations.Continue Reading False Claims Act Settlements to Know from Q1 2024
Register Now | Healthcare Fraud & Abuse Annual Review Webinar Replay
Bass, Berry & Sims released its 12th Annual Healthcare Fraud & Abuse Review on February 26, 2024. As a companion to the Review, we hosted a complimentary webinar which provided an overview and discussion of key focus areas covered in the Review. We are pleased to offer an encore presentation of this webinar on April 25, 2024.Continue Reading Register Now | Healthcare Fraud & Abuse Annual Review Webinar Replay
Register Now | HHS-OIG Year in Review Webinar Replay
In 2023, the U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG) offered the industry new and updated guidance tools and a late flurry of advisory opinions. Join us for a webinar in which we will provide a high-level overview of 2023’s most significant and helpful guidance documents.Continue Reading Register Now | HHS-OIG Year in Review Webinar Replay
Second Circuit Clarifies Anti-Kickback Statute’s Scienter Requirement
On March 12, the U.S. Court of Appeals for the Second Circuit issued an important decision that sheds light on the test for determining scienter under the federal Anti-Kickback Statute (AKS).Continue Reading Second Circuit Clarifies Anti-Kickback Statute’s Scienter Requirement
Download Now – 12th Annual Healthcare Fraud & Abuse Review
Bass, Berry & Sims is pleased to announce the release of the 12th annual Healthcare Fraud & Abuse Review examining important healthcare fraud developments in 2023. Continue Reading Download Now – 12th Annual Healthcare Fraud & Abuse Review